Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3454-3456

  Abe, Fumie ^a   Ueyama, Jun ^b   Kawasumi, Noriyo ^a   Nadai, Masayuki ^c   Hayashi, Tamon ^a   Kato, Miki ^a   Ohnishi, Masafumi ^a   Saito, Hiroko ^a   Takeyama, Naoshi ^a   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 2; PLASMA PROTEIN;

ANALBUMINEMIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIFUNGAL AGENTS; BLOOD PROTEINS; CHOLESTEROL, HDL; ECHINOCANDINS; GAMMA-GLOBULINS; LIPOPROTEINS; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN;

EID: 50949133945     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00396-08     Document Type: Article

References (20)

1. Abe, F., J. Ueyama, M. A. Kimata, M. Kato, T. Hayashi, M. Nadai, H. Saito, N. Takeyama, H. Noguchi, and T. Hasegawa. Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats. Life Sci., in press.
2. Bae, S. K., H. E. Kang, M. K. Kang, J. W. Kim, T. Kim, and M. G. Lee. 2006. Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats. J. Pharm. Sci. 95:998-1005.
3. Choi, Y. H., S. K. Bae, S. O. Kim, and M. G. Lee. 2007. Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: faster metabolism of 5-fluorouracil via CYP1A. Biopharm. Drug Dispos. 28:87-95.
4. Hebert, M. F., D. K. Blough, R. W. Townsend, M. Allison, D. Buell, J. Keims, and I. Bekersky. 2005. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 45:1018-1024.
5. Hebert, M. F., R. W. Townsend, S. Austin, G. Balan, D. K. Blough, D. Buell, J. Keims, and I. Bekersky. 2005. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 45:954-960.
6. Kaneko, H., Y. Yamato, Y. Teramura, T. Fujiwara, A. Suzuki, A. Kawarura, M. Terakawa, and A. Kagayama. 2002. Metabolites of micafungin in rats and dogs. Jpn. J. Chemother. 50(Suppl. 1):88-93.
7. Kim, E. J., and M. G. Lee. 2003. Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. Biopharm. Drug Dispos. 24:27-35.
8. Kim, E. J., A. K. Lee, S. H. Kim, S. G. Kim, and M. G. Lee. 2003. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagase analbuminemic rats. Drug Metab. Dispos. 31:194-201.
9. Kim, E. J., O. K. Suh, and M. G. Lee. 2003. Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci. 31:1231-1245.
10. Konishi, H., M. Sudo, M. Sumi, H. Morii, T. Minouchi, T. Aimoto, and A. Yamaji. 2005. Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure. Biol. Pharm. Bull. 28:556-559.
11. Mochizuki, N., K. Matsumoto, K. Ohno, T. Shimamura, H. Furukawa, S. Todo, and S. Kishino. 2006. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant. Proc. 38:3649-3650.
12. Mukai, T., T. Ohkuma, K. Nakahara, M. Terakawa, M. Shimizu, T. Uematsu, and J. Azuma. 2001. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects, abstr. A-30. Program Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Nagase, S., K. Shimamune, and S. Shumiya. 1979. Albumin-deficient rat mutant. Science 205:590-591.
14. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28:1805-1808.
15. Niwa, T., S. Inoue-Yamamoto, T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. 28:1813-1816.
16. Sakaeda, T., K. Iwaki, M. Kakumoto, M. Nishikawa, T. Niwa, J. S. Jin, T. Nakamura, K. Nishiguchi, N. Okamura, and K. Okumura. 2005. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J. Pharm. Pharmacol. 57:759-764.
17. Seibel, N. L., C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W. M. Lau, D. P. Facklam, D. N. Buell, and T. J. Walsh. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-3324.
18. Takada, K., T. Kawamura, M. Inai, S. Masuda, T. Oka, Y. Yoshikawa, N. Shibata, H. Yoshikawa, O. Ike, H. Wada, and S. Hitomi. 1999. Pharmacokinetics of cisplatin in analbuminemic rats. Biopharm. Drug Dispos. 20:421-428.
19. Yamato, Y., H. Kaneko, T. Hashimoto, M. Katashima, K. Ishibashi, A. Kawarura, M. Terakawa, and A. Kagayama. 2002. Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jpn. J. Chemother. 50(Suppl. 1):74-79.
20. 14C] micafungin to rats. Jpn. J. Chemother. 50(Suppl. 1):80-87.